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DISCUSSION
Dr Boulos Toursarkissian (San Antonio, Tex). The results in
this report are certainly far from stellar. Five of 13 limbs salvaged
still had rest pain or ulcers, and restenosis was significant. Admit-
tedly, it was a challenging group of patients. It has also been our
anecdotal experience that atherectomy is not free from restenosis.
We have also recently reported on an extremely high rate of
embolization in a series of patients who underwent femoral
atherectomy and had distal embolic protection devices routinely
used. The incidence was such that we now routinely use filters
when doing atherectomy.
With this said, and in an effort to put the results of this paper
in context, I have a number of questions for the authors.
1. How do you decide in your practice on when to use atherec-
tomy, and why did you choose this modality in these patients? Is
it a last-ditch effort or your primary treatment modality?
2. Do you feel that the adjunctive procedures you carried out
especially in the outflow vessels impacted your results in any
way?
3. A large number of your patients had renal failure. These are the
ones who tend to get amputations despite patent bypasses.
Were the atherectomy results in this subgroup similar to the
patients with no renal failure?
4. You report a primary patency of 43% at 12 months. Anecdot-
ally, how does this rate compare, for instance, to claudicants
you have treated with SilverHawk and also to patients with
critical ischemia you have treated with bypass?
5. Given the restenosis, what is your follow-up routine after
atherectomy? Do you use duplex, and, if so, how frequently do
you obtain studies?
Finally, I wish to congratulate the authors for reporting their
results. I feel their series of cases represents a real-life experience of
patients with true critical limb ischemia and clearly demonstrates
that atherectomy is not the silver bullet that is being marketed. It
clearly has and will have a role in the treatment of patients with
peripheral vascular disease. It is our challenge as vascular surgeons
to define its appropriate place and report its short-term and long-
term successes, limitations, and proper use.
Dr.Minion. In this paper, we looked specifically at a group of
patients that are very high risk. I believe that there is a common
theme among our paper, the paper presented immediately before
us, and the two papers after us that these patients do not do very
well with endovascular interventions. Again, these patients re-
spond very differently than claudicators. Therefore, to answer your
fourth question regarding our outcomes in claudicators, unfortu-
nately, I have very little data since we usually treat claudicators
nonoperatively. We offer this intervention, but only after a trial of
medical therapy and a long discussion on the natural history of
claudication and the risks and benefits of intervention. Once they
understand their risk of limb loss is low, most of our patient
population is satisfied with non-operative management.
In terms of bypass, we did not do a concurrent controlled trial
on our bypass outcomes. I would assume that our bypass outcomes
are similar to those reported in the literature which is about a 66%
five-year patency rate for vein bypass in critical limb ischemia.
In terms of our selection criteria for performing atherectomy,
when we initially started using atherectomy, we thought it was an
ideal procedure because you could treat long segment stenosis with
a single device. We were extremely encouraged by our early results.
So much so that it quickly became our first line therapy. Unfortu-
nately we soon began experiencing significant restenosis, prompt-
ing us to re-think this strategy. I still don’t know the proper use for
this catheter, but I don’t think it works very well in TASCC lesions
with critical limb ischemia. On the other hand, many of our
patients do not have vein and are very high risk. I think we can
achieve reasonable limb salvage in patients with lower life expect-
ancies, justifying the continued use of these or other endovascular
procedures in such patients.
In terms of our adjuvant procedures, not surprisingly, we
noted that isolated TASC C lesions do not usually cause critical
limb ischemia. Almost all of our patients had inflow disease or
significant outflow disease. I think it is important that you treat all
levels of disease. Interestingly, we actually found a higher resteno-
sis rate in our patients that underwent an adjuvant inflow proce-
dure compared to the patients undergoing an adjuvant outflow
procedure. However, the numbers are small, and I am not sure of
the validity of such subgroup analysis.
In terms of the effect of renal failure, we did not specifically
break out that subgroup for analysis. Again, the numbers are too
small. However, the prevalence of co-morbidities in our cohort
must be taken into account when comparing these results to other
endovascular procedures.
In terms of follow-up, our general routine, barring a return of
clinical symptoms, is to follow up at onemonth, six months, twelve
months, and then annually thereafter.
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 3 Yancey et al 509
